Search

Cholecystokinin

This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system. … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.

Trimethadione

An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

Pentaerythritol tetranitrate

It is formed by reacting pentaerythritol (C5H12O4), an alcohol commonly used in paints and varnishes, with nitric acid (HNO2). The reacting solution is chilled to precipitate the PETN. … Interestingly, this drug was studied for potential benefits in chronic ischemic heart failure patients.

Tafenoquine

Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35677] It was FDA approved on July 20, 2018.[L3770]

Propiverine

Overactive bladder syndrome affects millions of elderly individuals in the United States and shows equal prevalence in men and women. … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].

Degarelix

Reduction in testosterone is important in treating men with advanced prostate cancer. … FDA approved on December 24, 2008.

Bromotheophylline

[A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113]

Omega-3-carboxylic acids

The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]

1,2-Docosahexanoyl-sn-glycero-3-phosphoserine

Eflapegrastim

in which the patient develops an infection during a period of significant neutropenia. … chemotherapy-induced neutropenia, including FN.